North America Sleep Disorder Treatment Market
Tamanho do mercado em biliões de dólares
CAGR : %
Período de previsão |
2021 –2028 |
Tamanho do mercado (ano base ) | USD 4,945.53 Million |
Tamanho do mercado ( Ano de previsão) | USD 9,469.97 Million |
CAGR |
|
Principais participantes do mercado |
>Mercado de tratamento de perturbações do sono da América do Norte, por tipo (Insónia, Apneia do Sono, Síndrome das Pernas Inquietas (SPI), Narcolepsia e outros), Tratamento (Terapia Farmacológica, Terapia Mecânica, Dispositivos de Avanço Mandibular, Estimulador do Nervo Hipoglosso, Cirurgia e Outros), Via de Administração (Oral, Parentérica e Outras), Tipo de Medicamento (de Marca e Genéricos), Tipo de População (Crianças e Adultos), Utilizador Final (Hospitais, Clínicas Especializadas, Assistência Domiciliária, Bloco Operatório Ambulatório e Outros), Canal de Distribuição ( Concurso direto, farmácia hospitalar, farmácia de retalho, farmácia online e outros), país (EUA, Canadá e México), tendências e previsão da indústria para 2028
Análise de mercado e insights : Mercado de tratamento de distúrbios do sono na América do Norte
Prevê-se que o mercado de tratamento de distúrbios do sono na América do Norte atinja os 9.469,97 milhões de dólares até 2028, face aos 4.945,53 milhões de dólares em 2020, crescendo a um CAGR de 8,6% no período previsto de 2021 a 2028. O mercado de tratamento de distúrbios do sono na América do Norte deverá crescer devido o aumento da prevalência de distúrbios do sono, como apneia do sono, insónia e narcolepsia em todo o mundo.
Os distúrbios do sono, como a apneia do sono, a narcolepsia ou a insónia, são distúrbios médicos nos quais o doente tem dificuldade na manutenção do sono ou no início do sono. Este distúrbio causa funções mentais, físicas, sociais e emocionais irregulares. Os distúrbios do sono são tratados através de diferentes opções de tratamento de acordo com os sintomas dos doentes. A maioria dos doentes com apneia do sono é tratada através de terapias mecânicas. As terapêuticas farmacológicas como os antidepressivos, canabidiois, benzodiazepinas e estimulantes são utilizadas para o tratamento da insónia, narcolepsia e síndrome das pernas inquietas, entre outras. Os dispositivos intraorais também são utilizados para prevenir o ressonar, criando canais das vias aéreas, de forma a criar espaço para as trocas gasosas adequadas.
Prevê-se que o crescimento do mercado seja impulsionado por fatores como o aumento da incidência de depressão e outros distúrbios médicos, aumento da população geriátrica em todo o mundo, mudanças no estilo de vida, falta de sono de qualidade que impulsionaram o crescimento do mercado de tratamento de distúrbios do sono. A introdução de novos medicamentos e dispositivos médicos aprovados pela FDA para o tratamento destes distúrbios do sono atua como uma oportunidade para o crescimento do mercado de tratamento dos distúrbios do sono. No entanto, os vencimentos de patentes ou o penhasco de patentes dos principais medicamentos para o tratamento de distúrbios do sono e os efeitos secundários associados a estes medicamentos restringem o crescimento do mercado de tratamento de distúrbios do sono.
O relatório de mercado de tratamento de distúrbios do sono fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado , aprovações de produtos, decisões estratégicas, lançamentos de produtos. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito do mercado de tratamento de perturbações do sono na América do Norte e dimensão do mercado
O mercado de tratamento de distúrbios do sono da América do Norte está segmentado com base no tipo, tratamento, via de administração, tipo de medicamento, tipo de população, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo, o mercado de tratamento de distúrbios do sono está segmentado em insónia, apneia do sono, síndrome das pernas inquietas (SPI), narcolepsia e outros. Em 2021, o segmento da insónia domina o mercado devido à crescente consciencialização sobre a doença, cada vez mais pessoas adotam as opções de tratamento.
- Com base no tratamento, o mercado de tratamento de distúrbios do sono está segmentado em terapia farmacológica, terapia mecânica, dispositivos de avanço mandibular, estimulador do nervo hipoglosso, cirurgia e outros. Em 2021, o segmento da terapia farmacológica está a dominar o mercado devido ao aumento dos produtos pipeline para o tratamento de distúrbios do sono pelos principais players do mercado.
- Com base na via de administração, o mercado de tratamento das perturbações do sono está segmentado em oral, parentérica e outras. Em 2021, o segmento oral domina o mercado devido à forma económica e segura de administração levando ao aumento da captação por parte dos pacientes sofridos.
- Com base no tipo de medicamento, o mercado de tratamento de distúrbios do sono está segmentado em genéricos e de marca. Em 2021, o segmento dos genéricos está a dominar o mercado devido à natureza económica e à fácil disponibilidade dos medicamentos genéricos para o tratamento de distúrbios do sono.
- Com base no tipo populacional, o mercado de tratamento de distúrbios do sono está segmentado em crianças e adultos. Em 2021, o segmento dos adultos está a dominar o mercado devido à disponibilidade de terapêuticas farmacológicas aprovadas pela FDA dos EUA para o tratamento de distúrbios do sono em adultos.
- Com base no utilizador final, o mercado de tratamento de distúrbios do sono está segmentado em hospitais, clínicas especializadas, assistência domiciliária, centro de cirurgia ambulatória e outros. Em 2021, o segmento hospitalar está a dominar o mercado, uma vez que os hospitais são o local privilegiado visitado pelos pacientes para qualquer procedimento ou cirurgia.
- On the basis of distribution channel, the sleep disorder treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is dominating the market because direct tender fulfils the need of physicians and patients as most of the facilities procure drugs from direct tenders.
Sleep Disorder Treatment Market Country Level Analysis
The sleep disorder treatment market is analysed and market size information is provided by the country, type, treatment, route of administration, drugs type, population type, end user, and distribution channel.
The countries covered in the sleep disorder treatment market report are the U.S., Canada and Mexico.
The U.S. is expected to dominate the market due to the increasing prevalence of sleep disorders among the population. Canada is expected to grow due to the increasing product portfolio of companies. Mexico is expected to grow because it is an emerging market and the market players are focusing more on providing different products.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
New product launches by manufactures is creating new opportunities for players in the sleep disorder treatment market
Sleep disorder treatment market also provides you with detailed market analysis for every country growth in sleep disorder treatment industry with sleep disorder treatment market sales, impact of advancement in the sleep disorder treatment market and changes in regulatory scenarios with their support for the sleep disorder treatment market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Sleep Disorder Treatment Market Share Analysis
Sleep disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to sleep disorder treatment market.
Alguns dos principais players que operam no mercado de tratamento de distúrbios do sono são a Jazz Pharmaceuticals, Inc., a Pfizer Inc., a Viatris Inc., a Arbor Pharmaceuticals, a Aurobindo Pharma USA (uma subsidiária da Aurobindo Pharma), a sanofi-aventis US LLC (uma subsidiária da Sanofi), Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Inc. (uma subsidiária da Lupin), Taj Pharmaceuticals Limited, Eli Lilly and Company, Mallinckrodt, Alembic Pharmaceuticals Limited, Apotex Inc., Dr. (uma subsidiária da Teva Pharmaceutical Industries Ltd.), Taro Pharmaceutical Industries Ltd., Koninklijke Philips NV, DeVilbiss Healthcare LLC, ResMed, SomnoMed, Oventus e BMC Medical Co., entre outros.
Muitos lançamentos e acordos de produtos são também iniciados pelas empresas de todo o mundo, que também estão a acelerar o mercado de tratamento de distúrbios do sono.
Por exemplo,
- Em julho de 2020, a Jazz Pharmaceuticals plc anunciou a aprovação da FDA para o seu medicamento denominado Xyway para a indicação de cataplexia e sonolência diurna excessiva em pessoas que vivem com narcolepsia na faixa etária superior a 15 anos. Esta nova terapêutica para distúrbios do sono da empresa, aprovada pela FDA dos EUA, aumentou a procura e as vendas do seu medicamento no mercado, levando a um aumento das receitas no futuro.
- Em junho de 2016, a Mylan NV lançou a versão genérica do medicamento nuvigil denominado comprimido de armodafinil para indicação de vigília em adultos com sonolência excessiva associada a apneia obstrutiva do sono, narcolepsia ou perturbação do trabalho por turnos. Este novo medicamento lançado pela empresa no mercado dos EUA aumentou a sua procura e vendas no mercado, levando ao aumento das vendas no futuro.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS
6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS
7.1.2 RISE IN THE GERIATRIC POPULATION
7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS
7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS
7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES
7.2 RESTRAINTS
7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS
7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS
7.2.3 EMERGENCE OF GENERICS
7.3 OPPORTUNITIES
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS IN THE U.S.
7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS
7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE
7.4 CHALLENGES
7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER
7.4.2 STRINGENT REGULATORY LANDSCAPE
7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE
8 IMPACT OF COVID-19 ON NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 INSOMNIA
9.2.1 INSOMNIA
9.2.2 CHILD INSOMNIA
9.2.3 OTHERS
9.3 SLEEP APNEA
9.3.1 OBSTRUCTIVE SLEEP APNEA
9.3.2 CENTRAL SLEEP APNEA
9.3.3 SNORING
9.3.4 INFANT SLEEP APNEA
9.3.5 OTHERS
9.4 RESTLESS LEGS SYNDROME (RLS)
9.5 NARCOLEPSY
9.5.1 TYPE 1
9.5.2 TYPE 2
10 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 PHARMACOLOGICAL THERAPY
10.2.1 CANNABIDIOL
10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS)
10.2.3 BENZODIAZEPINES
10.2.4 NON-BENZODIAZEPINE
10.2.5 MELATONIN RECEPTOR STIMULATOR
10.2.6 STIMULANTS
10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
10.2.8 TRICYCLIC ANTIDEPRESSANTS
10.2.9 SODIUM OXYBATE (XYREM)
10.2.10 OTHERS
10.3 MECHANICAL THERAPY
10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE)
10.3.2 BI-LEVEL PAP
10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP
10.3.4 ADAPTIVE SERVO-VENTILATION (ASV)
10.4 MANDIBULAR ADVANCEMENT DEVICES
10.5 HYPOGLOSSAL NERVE STIMULATOR
10.6 SURGERY
10.6.1 SOMNOPLASTY
10.6.2 TONSILLECTOMY
10.6.3 NASAL SURGERY
10.6.4 OTHERS
10.7 OTHERS
11 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 PILLS
11.2.3 OTHERS
11.3 PARENTERAL
11.4 OTHERS
12 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
12.3.1 XYREM
12.3.2 EFFEXOR XR
12.3.3 AMBIEN
12.3.4 PRISTIQ
12.3.5 ZENZEDI
12.3.6 VYVANSE
12.3.7 OTHERS
13 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULT
13.3 CHILDREN
14 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 AMBULATORY SURGICAL CENTER
14.6 OTHERS
15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
15.6 OTHERS
16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 JAZZ PHARMACEUTICALS, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 ELI LILLY AND COMPANY
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 VIATRIS INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 RESMED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 MALLINCKRODT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 KONINKLIJKE PHILIPS N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ALEMBIC PHARMACEUTICALS LIMITED
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 AMNEAL PHARMACEUTICALS LLC
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 APOTEX INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 ARBOR PHARMACEUTICALS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 BMC MEDICAL CO.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 DEVILBISS HEALTHCARE LLC
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.15 DR. REDDY’S LABORATORIES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 HIKMA PHARMACEUTICALS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 OVENTUS
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SOMNOMED
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 TAJ PHARMACEUTICALS LIMITED
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENT
19.22 TARO PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENT
19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
TABLE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS FOR SLEEP DISORDER TREATMENT
TABLE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 6 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 9 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 10 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 11 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 13 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 14 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 U.S. SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 U.S. INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 U.S. SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 U.S. NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2019-2028 (USD MILLION)
TABLE 38 U.S. SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 39 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT , 2019-2028 (USD MILLION)
TABLE 40 U.S. MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 41 U.S. SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 42 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 U.S. ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 45 U.S. BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 46 U.S. SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 47 U.S. SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 48 U.S. SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 CANADA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 CANADA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 CANADA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 CANADA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 53 CANADA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 54 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 55 CANADA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 56 CANADA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 57 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 58 CANADA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 59 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 60 CANADA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 61 CANADA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 62 CANADA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 CANADA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 MEXICO SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 MEXICO NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 68 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 69 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 70 MEXICO MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 71 MEXICO SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 72 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 73 MEXICO ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 75 MEXICO BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 76 MEXICO SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 77 MEXICO SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 MEXICO SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Lista de Figura
FIGURE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 10 RISING PREVALENCE OF SLEEPING DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 INSOMNIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
FIGURE 13 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 14 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 15 PROPORTION OF AMERICAN TEENS (13- TO 18- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020
FIGURE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020
FIGURE 21 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020-2028 (USD MILLION)
FIGURE 22 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, CAGR (2020-2028)
FIGURE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 25 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 26 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 27 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020
FIGURE 29 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020-2028 (USD MILLION)
FIGURE 30 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, CAGR (2020-2028)
FIGURE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020
FIGURE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 34 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 35 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020
FIGURE 37 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 38 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 45 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 46 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE (2020-2028)
FIGURE 49 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.